IL-17A & IL-17F

IL-17A & IL-17F Informations sur la molécule

Nom anglais	Interleukin-17F	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	5	Alias de la cible	Cytokine ML-1，Interleukin-17F，IL17F，Interleukin 17F，IL-17F，CANDF6，ML-1，ML1
Phase de R&D la plus avancée	NDA/BLA

Nom anglais	Interleukin-17F
Alias de la cible	Cytokine ML-1，Interleukin-17F，IL17F，Interleukin 17F，IL-17F，CANDF6，ML-1，ML1
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	5
Phase de R&D la plus avancée	NDA/BLA

IL-17A & IL-17F Liste de produits

Attribut
Protein (3)
Bibliothèque de produits
En ligne (3)
Espèces
Human (2)Mouse (1)
Étiquette
His Tag & Avi Tag (1)His Tag & Strep Tag (1)His Tag (1)
Marqueur
Biotin-labeled (1)Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
ILF-H52W6	Human	HEK293	Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag, low endotoxin (MALS verified)	Ajouter au panier
ILF-H82W1	Human	HEK293	Biotinylated Human IL-17A&IL-17F Protein, Avitag™,His Tag	Ajouter au panier
ILF-M52H3	Mouse	HEK293	Mouse IL-17A&IL-17F Heterodimer Protein, His Tag (MALS verified)	Ajouter au panier

Quantité totale3

IL-17A & IL-17FContexte de la molécule

Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

IL-17A & IL-17FAlias de la molécule

IL-17A,Interleukin-17A,CTLA-8,IL-17,IL-17F,Interleukin-17F,Cytokine ML-1,IL17A＆IL17F

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Sonelokimab	ALX-0761; MSB-0010841; M-1095	Phase 3 Clinical	Ablynx Nv	Arthritis, Psoriatic; Hidradenitis Suppurativa; Psoriasis	Details
DMT-310	DMT-310	Phase 3 Clinical	Dermata	Acne Vulgaris; Rosacea	Details
ORKA-002	ORKA-002; PR-029; ORKA-021	Phase 2 Clinical	Paragon Therapeutics Inc	Arthritis, Psoriatic; Plaque psoriasis; Psoriasis	Details
PN-881	PN-881	Phase 1 Clinical	Protagonist Therapeutics Inc	Dermatitis; Psoriasis	Details
HY-1770	HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770	Phase 1 Clinical	Suzhou Pharmavan Co Ltd	Dermatitis, Atopic; Plaque psoriasis	Details